Neil Martin

机构：AstraZeneca (United Kingdom), Royal Hospital for Children, AstraZeneca (Switzerland), NIHR Leicester Biomedical Research Centre · ORCID：0000-0003-3115-3328

发表论文 105 篇 · 总被引 2350 次 · h-index 28

代表论文

• Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults (2024 · American Journal of Respiratory and Critical Care Medicine · 被引 125)
• Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials (2025 · The Lancet Respiratory Medicine · 被引 83)
• Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies (2024 · European Respiratory Journal · 被引 44)
• Exploring Definitions and Predictors of Response to Biologics for Severe Asthma (2024 · The Journal of Allergy and Clinical Immunology In Practice · 被引 34)
• Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma (2024 · Frontiers in Immunology · 被引 29)
• Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps (2024 · Advances in Therapy · 被引 21)